Skip to content
value.today

Newlink Genetics Corp.

Total raised
$41 M
3 rounds on record
Latest round
$13 M
Dec 2010
First round on record
Feb 2008
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Newlink Genetics Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2011$10 MIssued in a merger or acquisition$10 to $50 million

Newlink Genetics Corp.: Private sale, Jan 2011

Investors in this round

40 investors had bought by the notice of Aug 17, 2011: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Newlink Genetics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Link, M.D. · Executive Officer, Director
  • Gordon H. Link · Executive Officer
  • Kenneth J. Lynn · Executive Officer
  • Nicholas Vahanian, M.D. · Executive Officer
  • David J. Lundquist · Director
  • Ernest H. Talarico, III · Director
  • Joseph J. Saluri · Director
  • Paul J. Edick · Director
  • Sarah J. Alexander, M.D. · Director
  • Tom H. Raffin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “"Merger of BioProtection Systems Corporation (""BPS""), a majority-owned subsidiary of the Company, into the Company in order for the Company to acquire the minority interest in BPS. Shares of BPS were converted into shares of Series E Preferred Stock."”

Signed by Gordon Link, Cfo. Source: SEC Form D and 2 amendments, newest notice filed Aug 17, 2011. Read the notice at the SEC.

equitySEC
Dec 2010$13 MNo. 3$10 to $50 million

Newlink Genetics Corp.: Raise no. 3, Dec 2010

Investors in this round

38 investors had bought by the notice of Sep 22, 2011: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Newlink Genetics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Link, M.D. · Executive Officer, Director
  • Gordon H. Link · Executive Officer
  • Kenneth J. Lynn · Executive Officer
  • Nicholas Vahanian, M.D. · Executive Officer
  • David J. Lundquist · Director
  • Ernest H. Talarico, III · Director
  • Joseph J. Saluri · Director
  • Paul R. Edick · Director
  • Sarah J. Alexander, M.D. · Director
  • Tom H. Raffin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gordon Link, Cfo. Source: SEC Form D and 1 amendment, newest notice filed Sep 22, 2011. Read the notice at the SEC.

equitySEC
Jul 2009$8 MNo. 2$2 to $10 million

Newlink Genetics Corp.: Raise no. 2, Jul 2009

Investors in this round

1 investor had bought by the notice of Jul 28, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Newlink Genetics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$2,500,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Link, M.D. · Executive Officer, Director
  • Gordon H. Link · Executive Officer
  • Kenneth Lynn · Executive Officer
  • Nicholas Vahanian, M.D. · Executive Officer
  • David J. Lundquist · Director
  • Ernest Talarico, III · Director
  • Sarah J. Alexander, M.D. · Director
  • Tom Raffin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “New offering of Series D Preferred”

Signed by Gordon Link, Cfo. Source: SEC Form D, newest notice filed Jul 28, 2009. Read the notice at the SEC.

equitySEC
Feb 2008$21 MNo. 1$10 to $50 million

Newlink Genetics Corp.: Raise no. 1, Feb 2008

Investors in this round

114 investors had bought by the notice of Jul 28, 2009: 114 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Newlink Genetics Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $30 M offered; $9 M still to sell
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$4,593,363 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Link, M.D. · Executive Officer, Director
  • Gordon H. Link · Executive Officer
  • Kenneth Lynn · Executive Officer
  • Nicholas Vahanian, M.D. · Executive Officer
  • David J. Lundquist · Director
  • Ernest Talarico, III · Director
  • Sarah J. Alexander, M.D. · Director
  • Tom Raffin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Initial offering of $25,000,000 of Series C Preferred was expanded to $30,000,000”
  • On the use of proceeds: “Executive officers (EOs) and directors are not directly compensated with proceeds. Proceeds are applied to working capital purposes, including payment of EOs' salaries. Figure provided equals 3 years' of 2009 level salaries for the 4 named EOs.”

Signed by Gordon Link, Cfo. Source: SEC Form D, newest notice filed Jul 28, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Newlink Genetics Corp. chose not to state its revenue in its newest notice of a funding round (Sep 2011).

    SEC Form D · Sep 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2011

That is all the official record says: Newlink Genetics Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Newlink Genetics Corp.
InvestorKindAmountRoundRoleSource
Charles J. Link Jr.Personnot statednot statedHeld Series E preferred stock, director (Form 3, 2011)SEC Form 3
Ernest Talarico IIIPersonnot statednot statedHeld Series E preferred stock, director (Form 3, 2011)SEC Form 3
Joseph SaluriPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2011)SEC Form 3
Nicholas N. VahanianPersonnot statednot statedHeld Series A and E preferred stock (Form 3, 2011)SEC Form 3
Sarah AlexanderPersonnot statednot statedHeld Series AAA and C preferred stock, director (Form 3, 2011)SEC Form 3
Stine Seed Farm, Inc.Venture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Thomas A. RaffinPersonnot statednot statedHeld Series E preferred stock, director (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 114 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Newlink Genetics Corp.
NameRoleNamed in
Charles Link, M.D.Executive officerSep 2011
Gordon H. LinkExecutive officerSep 2011
Kenneth J. LynnExecutive officerSep 2011
Nicholas Vahanian, M.D.Executive officerSep 2011
Kenneth LynnExecutive officerJul 2009
Charles Link, M.D.DirectorSep 2011
David J. LundquistDirectorSep 2011
Ernest H. Talarico, IIIDirectorSep 2011
Joseph J. SaluriDirectorSep 2011
Paul R. EdickDirectorSep 2011
Sarah J. Alexander, M.D.DirectorSep 2011
Tom H. Raffin, M.D.DirectorSep 2011
Paul J. EdickDirectorAug 2011
Ernest Talarico, IIIDirectorJul 2009
Tom Raffin, M.D.DirectorJul 2009